# Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

> **NCT05166616** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 8 (actual)

## Conditions studied

- Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Lung Non-Small Cell Carcinoma
- Stage III Lung Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
- Unresectable Lung Non-Small Cell Carcinoma

## Interventions

- **PROCEDURE:** Biopsy
- **DRUG:** Osimertinib
- **DRUG:** Triptolide Analog

## Key facts

- **NCT ID:** NCT05166616
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-07
- **Primary completion:** 2027-10-28
- **Final completion:** 2027-10-28
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05166616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05166616, "Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05166616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*